Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

26 Jan 2012
by Working Group

Posted in TB Drug Development, TB News

TB R&D Weekly Update: SQ109 and PNU Compounds Additive

JAC cover

In this week’s article, we look at two drugs in our Global TB Drug Pipeline and how they interact with each other: SQ109 (class: Ethylenediamines, Sequella) and PNU-100480 (called Sutezolid, class: Oxazolidinone, Pfizer). Additional links to TB R&D news are included.

29 Sep 2011
by Working Group

Posted in Events, TB Drug Development, TB News

TB R&D Weekly Update: ICAAC and TB Drug Clinical Workshop

ICAAC

On September 16, the 4th International Workshop on Clinical Pharmacology of Tuberculosis Drugs was held adjacent to the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) which was held from September 17 to 19. Between the two meetings, there were many updates related to TB drug development. Additional links to TB R&D are included.

8 Sep 2011

TB R&D Weekly Update: TB Drug Updates in Future Medicinal Chemistry

fmccover

Last week we posted information about two special issues of Future Medicinal Chemistry focused on neglected diseases. Future Medicinal Chemistry (September 2011, Volume 3, Number 11) have a few articles on tuberculosis drug development. Additional links to TB R&D news are included.

12 Jul 2011
by Working Group

Posted in TB Drug Development, TB News

TB R&D Weekly Update: Early bactericidal activity of OPC-67683

compound-OPC67683

This week, we review a recent article published in the July issue of IJTLD on the TB drug candidate OPC-67683 whose new generic name is delamanid. Diacon, et al., present data showing that delamanid is safe, well-tolerated with significant early bactericidal activity. Links to additional TB R&D news is included.

25 May 2011
by Working Group

Posted in Announcements, TB News

Announcement: Promising TB vaccine candidate progresses to Phase I clinical trials

tbvi

The MTBVAC01 vaccine candidate, developed to protect people against tuberculosis, will start Phase I clinical trials early in 2012. This was announced by the Spanish biopharmaceutical company Biofabri. The candidate was developed by the University of Zaragoza, Spain and is part of the international portfolio of TuBerculosis Vaccine Initiative (TBVI). Tuberculosis causes almost two million deaths per year.

TB R&D Weekly Update: Marine Drug Discovery Symposium at the NYAS

NYAS

This week in TB R&D, we are highlighting a symposium hosted by The New York Academy of Sciences entitled “New Frontiers in Marine Drug Discovery” on May 20, 2011. This 1-day symposium will overview the current state of the art in Marine Biomedicine and its role in the context of the drug discovery process. Additional TB R&D news links are included.

10 Mar 2011

BIO Ventures for Global Health Launches New Online Tool

Picture1

This week BIO Ventures for Global Health launched a new online tool called the “Global Health Primer” which aims to be a clearinghouse of information geared to the biotech industry to encourage investments in neglected disease product development.

4 Mar 2011
by Working Group

Posted in Announcements, TB Drug Development, TB News

AstraZeneca Joins Sanofi-Aventis to Develop New TB Treatment

drugs

AstraZeneca has joined a consortium to fight tuberculosis around the world with French rival Sanofi-aventis, the University of Cambridge and other research organisations.

TB R&D Weekly Update: Podcast Interview with Philip Bourne

bourne

In this week”s TB R&D update, The WGND had the opportunity to talk with Dr. Bourne on a recent article published in PLoS Computational Biology in November 2010. Dr. Philip Bourne is a professor at University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Editor in Chief of PL0S Computational Biology. In the interview, Dr. Bourne discusses his present research, use of structural bioinformatics to inform drug discovery, and the need for open access in research. Also, links to additional news in TB R&D are included.

23 Nov 2010
by Working Group

Posted in Events, Front Lines of TB R&D, Uncategorized

WGND 2010 Annual Meeting: Panel Discussion

Following the guest speakers, several representatives from companies conducting clinical trials of TB drug candidates presented brief updates on progress made in the clinical development of their candidates. We recap the presentations here and offer .pdf downloads of the original presentations.